CHEK1 and neoplasm: The CHK protein kinase is essential to ensure ecDNA genome integrity, and CHK inhibitions could trigger preferential cell death in ecDNA+ tumour cells. BBI-355 is currently in clinical trials as a CHK1 inhibitor.